StemCell Therapy

Updated / Saturday, 11 Feb 2017 14:25

Denzel Washington said he has "no idea"why he has never been nominated for a BAFTAAward. The Hollywood star has won two acting Oscars during his decades-long career and is nominated this year for another two: best actor and best picture for Fences, which he both directed and stars in. On his lack of a nod from the British Academy of the Film and Television Arts, he told the Press Association: "I've never been nominated for a Bafta. "You'll have to ask them why, I have no idea. I've been nominated for eight Oscars, won two." He added: "Morgan Freeman and I have never been nominated for a BAFTA." Washington's Fences co-star Viola Davis has received a nod in the best supporting actress category at this year's BAFTAs, which take place on Sunday February 12 at London's Royal Albert Hall. The actor, 62, also discussed the current trend for stars using their acceptance speeches at awards ceremonies to air their views about politics. He said: "It's America. People have the right to do and say what they want. There's a feeling in the air."

Harry Styles' solo album almost ready for release

More here:
Denzel Washington baffled by BAFTA blindness - RTE.ie

SAN FRANCISCO, February 10, 2017 /PRNewswire/ --

Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today, with great sadness, announced the death of biotechnology legend Dr. Joseph Rubinfeld, who was an independent director of the Company. Dr. Rubinfeld is survived by his wife, Loretta, and children Bonnie, Randee, Susan and Steven and their respective families.

"Dr. Rubinfeld, a co-founder of Amgen Inc., represented the best of the biotechnology industry. He was pragmatic, brilliant, honest and caring and always focused on the needs of patients" said Dr. John Commissiong, Chief Scientific Officer at Amarantus. "Immediately prior to his passing, Dr. Joe was selflessly working very hard to help turn Amarantus around. We will honor his memory by accelerating that effort to the best of our abilities."

Obituary of Dr. Joe Rubinfeld: http://www.oakmontmortuary.com/book-of-memories/2807770/Rubinfeld-Joseph/obituary.php

Joseph Rubinfeld

Resident of Danville, CA

October 24, 1932 - December 26, 2016

Joseph "Dr. Joe" Rubinfeld, a resident of Danville, passed away unexpectedly on December 26, 2016, at his home at the age of 84. Joe was born on October 24, 1932 in Brooklyn, New York to Mechel and Mary Rubinfeld. He married his wife and soul mate Loretta Rubinfeld on March 1, 1958.

Joe attended City College of New York before attending Columbia University for graduate school where he earned a Ph.D. in Organic Chemistry. Over a career that spanned more than 60 years, Joe was instrumental in discoveries that truly changed the world.

Some of his achievements include invention of 10-second Polaroid film and the biodegradable detergent formula used in dishwashing detergents. For saving the Great Lakes with his biodegradable detergent formula, Joe was awarded the Commonwealth Award for Invention in 1985.

Joe was also active in the biotechnology and medical fields. His inventions, including the development of the antibiotics Amoxicillin and Cefadroxil, were directly responsible for saving millions of lives.

While his passion was science and invention, he also had a passion for business. In 1980, he co-founded Amgen, which would become the world's largest biotechnology company. Later in his career, he founded SuperGen, Inc. and then JJ Pharma, Inc. He was active on the corporate and scientific advisory boards of multiple other pharmaceutical companies. He loved working and inventing. He retired once but did not like it because as he said, "there's only so many times you can go to Hawaii or Europe."

Joe is survived by his loving wife of 58 years, Loretta; his son Steven and his wife Kathleen of Danville, his daughter Susan and her husband Joseph Iovino of Danville, his daughter Randee and her husband Kevin Rolens of Danville, and his daughter Bonnee. He is also survived by 10 grandchildren, 2 great grandchildren, his brother Julius Rubinfeld and his wife Leslie, sister Rosalyn Axelrod, and a large and loving extended family.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered from the Company's proprietary discovery engine PhenoGuard. AMBS also received 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc.

For further information please visit http://www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

Read More

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

Investor and Media Contact: Ascendant Partners, LLC Fred Sommer +1-732-410-9810 fred@ascendantpartnersllc.com

View original post here:
Amarantus Announces Passing of Biotechnology Legend Dr. Joseph Rubinfeld - Yahoo Finance

NICHOLAS MCBRIDE

Last updated17:58, February 12 2017

Palmerston North Hospital will have to call on a neighbouring region to help treat its arthritis patients.

A new rheumatologistwas expected to start in February, after its two specialists retired and resigned,respectively, last year.

However, the new doctor will now not start until May, meaning the hospital will have to call on Hawke's Bay for support.

READ MORE: * Concerns raised over shortage of arthritis specialists and delays in replacements * Arthritis sufferer told hospital department will close - DHB denies this

That has prompted Arthritis New Zealand to say the condition is not prioritised in the health system.

Arthritis NZ chief executive Sandra Kirby said the specialist shortage was a "pretty well documented reality".

"We have been concerned for many years about a shortage of rheumatologists in New Zealand.

"It has been an issue for more than a decade. It is not a new phenomenon."

Kirby said arthritis was not viewed as a priority in the New Zealand health system, despite 620,000 people living with the condition.

"Manawatu has been well served [in the past], so this is disappointing."

She expected patients would still get a good service from the Hawke's Bay staff.

MidCentral DHB clinical services and transformation general manager Mike Grant said the new rheumatologist was relocating to New Zealand from the United Kingdom.

"Originally, the doctor was scheduled to begin earlier in 2017, however, the relocation process has taken longer than envisaged."

"In the interim, a rheumatologist based in the Hawke's Bay will provide follow-up clinics at MidCentral Health, as well as seeing urgent patients referred to the service.

"Support for inpatient management will also be available to senior medical officers, ensuring continuity of the rheumatology service for all patients requiring this care."

In a MidCentral committee agenda, Grant said rheumatology patients tended to have a higher proportion of chronic, long-term conditions, rather than acute cases that require urgent attention.

"These arrangements will ensure there is capacity to see any urgent patients referred while we await the arrival of our new specialist."

-Stuff

Read more:
Palmerston North Hospital calls on neighbour to treat arthritis patients - Manawatu Standard

Statistically there are more than 10 million cases of arthritis reported in India every year, and innumerable others that arent. Clinically speaking arthritis is more commonly seen in women, since they have a tendency to gain weight, especially Indian women, which in turn stresses the joints leading to the condition. Erratic intake of calcium is another precipitating factor. Osteoarthritis is the most common form of arthritis, which causes pain, inflammation and reduced motion in the joints. It typically affects the hands, knees, hips and the spine. The condition withers the cartilage, the slippery tissue that covers the ends of bone in a joint. When a person loses cartilage, the bones rub together, this can permanently damage the joint. Rheumatoid arthritis on the other hand is an autoimmune disease, which affects the entire body since there is an abnormal response of the immune system. In rheumatoid arthritis, the body's immune system attacks its own tissues, including joints and internal organs in some cases. Rheumatoid Arthritis is more incapacitating than osteoarthritis. The pain associated with arthritis depends on the stage, the symptoms are directly proportional to the stage. The early arthritis patients respond better as opposed to patients with an advanced condition, who have constant pain in joints throughout the day. The most commonplace joint to be affected is the knee, though there are also arthritis cases of shoulder, hip and other smaller joints. Early signs shall help more so with inflammatory arthritis, for instance Rheumatoid arthritis. Patients may complain of early morning stiffness, and if someone has this disorder the stiffness should last 30 to 40 minutes. It is suggested that if a patient goes through morning stiffness, and swelling in small joints, they should consult an Orthopedic Surgeon or a Rheumatologist at the earliest, since this condition if unchecked can be extremely detrimental for the joints. People in India normally resort to self-medication for alleviating pains. They allow the condition to go undiagnosed for years, and consult a clinician only when hands and feet get deformed and the pain becomes unbearable.

There is very little awareness concerning arthritis; therefore, it is imperative that people know more about it and how dreadful it can be. If left unattended, its most devastating side effect being that it can leave people incapacitated for life.

Ways to prevent and treat arthritis

Next week: How to spot early signs of thyroid-related diseases and treat them

Aashish Chaudhry

http://bsmedia.business-standard.com/_media/bs/wap/images/bs_logo_amp.png 177 22

See the original post:
Fit & Proper: How to prevent the onset of arthritis - Business Standard

OCASCR scientist Lin Liu at work. Photo provided.

Working together, scientists from Oklahoma State University, the University of Oklahoma Health Sciences Center and the Oklahoma Medical Research Foundation are advancing adult stem cell research to treat some of todays most devastating diseases.

Under the umbrella of the Oklahoma Center for Adult Stem Cell Research (OCASCR), created with funding from the Oklahoma Tobacco Settlement Endowment Trust, these scientists have amassed groundbreaking findings in one of the fastest growing areas of medical research.

We have made exciting progress, said OCASCR scientist Lin Liu, director of the Oklahoma Center for Respiratory and Infectious Diseases and director of the Interdisciplinary Program in Regenerative Medicine at Oklahoma State University.

We can convert adult stem cells into lung cells using our engineering process in petri dishes, which offers the possibility to repair damaged lung tissues in lung diseases, said Liu, whose research primarily focuses on lung and respiratory biology and diseases.

Using our engineered cells, we can also reverse some pathological features. These studies give us hope for an eventual application of these cells in humans.

Adult stem cells in the body are capable of renewing themselves and becoming various types of cells.

Until recently, stem cell treatments were largely restricted to blood diseases. However, new studies suggest many other types of adult stem cells can be used for medical treatment, and the Oklahoma Center for Adult Stem Cell Research was created to promote this branch of research.

OCASCR scientist Lin Liu and his team discussing their work. Photo provided.

Liu said the discipline provides hope for many ailments.

What most fascinated me in stem cell research is the hope that we may be able to use stem cells from our own body; for example, bone marrow or fat tissues to cure lung diseases, Liu said.

It is impossible to know exactly which diseases will respond to treatments.However, results of early experiments suggest many diseases should benefit from this type of research, including lung, heart, Alzheimers and Parkinsons diseases, as well as cancer, diabetes and spinal cord injuries. The field is often referred to as regenerative medicine, because of the potential to create good cells in place of bad ones.

While the application of stem cells can be broad, Liu hopes that his TSET-funded work will help develop treatments for diseases caused by tobacco use.

The goal of my research team is to find cures for lung diseases, Liu said. One such disease is chronic obstructive pulmonary disease (COPD).

COPD is the third leading cause of death in the country and cigarette smoking is the leading cause of COPD.

Cigarette smoking is also a risk factor for another fatal lung disease, idiopathic pulmonary fibrosis (IPF), which has a mean life expectancy of 3 to 5 years after diagnosis, he added.

There is no cure for COPD or IPF. The current treatments of COPD and IPF only reduce symptoms or slow the disease progression.

Using OCASCR/TSET funding, my team is researching the possibility to engineer adult stem cells using small RNA molecules existing in the body to cure COPD, IPF and other lung diseases such as pneumonia caused by flu, Liu said.

This is vital research, considering that more than11 million peoplehave been diagnosed with COPD, but millions more may have the disease without even knowing it, according to the American Lung Association.

Despite declining smoking rates and increased smokefree environments, tobacco use continues to cause widespread health challenges and scientists will continue working to develop treatments to deal with the consequences of smoking.

We need to educate the public more regarding the harms of cigarette smoking, Liu said. My research may offer future medicines for lung diseases caused by cigarette smoking.

Under the umbrella of the Oklahoma Center for Adult Stem Cell Research (OCASCR), created with funding from the Oklahoma Tobacco Settlement Endowment Trust, these scientists have amassed groundbreaking findings in one of the fastest growing areas of medical research. Photo provided.

Liu has been conducting research in the field of lung biology and diseases for more than two decades.

However, his interests in adult stem cell therapy began in 2010 when OCASCR was established through a grant with TSET, which provided funding to Oklahoma researchers for stem cell research.

I probably would have never gotten my feet into stem cell research without OCASCR funding support, he said. OCASCR funding also facilitated the establishment of the Interdisciplinary Program in Regenerative Medicine at OSU.

These days, Liu finds himself fully immersed in the exciting world of adult stem cell research and collaborating with some of Oklahomas best scientific minds.

Dr. Liu and his colleagues are really thriving. It was clear seven years ago that regenerative medicine was a hot topic and we already had excellent scientists in the Oklahoma, said Dr. Paul Kincade, founding scientific director of OCASCR. All they needed was some resources to re-direct and support their efforts. OSU investigators are using instruments and research grants supplied by OCASCR to compete with groups worldwide. TSET can point to their achievements with pride.

The Oklahoma Center for Adult Stem Cell Research represents collaboration between scientists all across the state, aiming to promote studies by Oklahoma scientists who are working with stem cells present in adult tissues.

The center opened in 2010 and has enhanced adult stem cell research by providing grant funding for researchers, encouraging recruitment of scientists and providing education to the people of Oklahoma.

We are fortunate that the collaboration at the Oklahoma Center for Adult Stem Cell Research is yielding such positive results, said John Woods, TSET executive director. This research is leading to ground breaking discoveries and attracting new researchers to the field. TSET is proud to fund that investments for Oklahomans.

Funding research is a major focus for TSET and it comes with benefits reaching beyond the lab. For every $1 TSET has invested at OCASCR, scientists have been able to attract an additional $4 for research at Oklahoma institutions, TSET officials said.

TSET also supports medical research conducted by the Stephenson Cancer Center and the Oklahoma Tobacco Research Center.

For more information, visit http://www.ocascr.org.

See original here:
OCASCR scientists make progress in TSET-funded adult stem cell research - NewsOK.com

OCASCR scientist Lin Liu at work. Photo provided.

Working together, scientists from Oklahoma State University, the University of Oklahoma Health Sciences Center and the Oklahoma Medical Research Foundation are advancing adult stem cell research to treat some of todays most devastating diseases.

Under the umbrella of the Oklahoma Center for Adult Stem Cell Research (OCASCR), created with funding from the Oklahoma Tobacco Settlement Endowment Trust, these scientists have amassed groundbreaking findings in one of the fastest growing areas of medical research.

We have made exciting progress, said OCASCR scientist Lin Liu, director of the Oklahoma Center for Respiratory and Infectious Diseases and director of the Interdisciplinary Program in Regenerative Medicine at Oklahoma State University.

We can convert adult stem cells into lung cells using our engineering process in petri dishes, which offers the possibility to repair damaged lung tissues in lung diseases, said Liu, whose research primarily focuses on lung and respiratory biology and diseases.

Using our engineered cells, we can also reverse some pathological features. These studies give us hope for an eventual application of these cells in humans.

Adult stem cells in the body are capable of renewing themselves and becoming various types of cells.

Until recently, stem cell treatments were largely restricted to blood diseases. However, new studies suggest many other types of adult stem cells can be used for medical treatment, and the Oklahoma Center for Adult Stem Cell Research was created to promote this branch of research.

OCASCR scientist Lin Liu and his team discussing their work. Photo provided.

Liu said the discipline provides hope for many ailments.

What most fascinated me in stem cell research is the hope that we may be able to use stem cells from our own body; for example, bone marrow or fat tissues to cure lung diseases, Liu said.

It is impossible to know exactly which diseases will respond to treatments.However, results of early experiments suggest many diseases should benefit from this type of research, including lung, heart, Alzheimers and Parkinsons diseases, as well as cancer, diabetes and spinal cord injuries. The field is often referred to as regenerative medicine, because of the potential to create good cells in place of bad ones.

While the application of stem cells can be broad, Liu hopes that his TSET-funded work will help develop treatments for diseases caused by tobacco use.

The goal of my research team is to find cures for lung diseases, Liu said. One such disease is chronic obstructive pulmonary disease (COPD).

COPD is the third leading cause of death in the country and cigarette smoking is the leading cause of COPD.

Cigarette smoking is also a risk factor for another fatal lung disease, idiopathic pulmonary fibrosis (IPF), which has a mean life expectancy of 3 to 5 years after diagnosis, he added.

There is no cure for COPD or IPF. The current treatments of COPD and IPF only reduce symptoms or slow the disease progression.

Using OCASCR/TSET funding, my team is researching the possibility to engineer adult stem cells using small RNA molecules existing in the body to cure COPD, IPF and other lung diseases such as pneumonia caused by flu, Liu said.

This is vital research, considering that more than11 million peoplehave been diagnosed with COPD, but millions more may have the disease without even knowing it, according to the American Lung Association.

Despite declining smoking rates and increased smokefree environments, tobacco use continues to cause widespread health challenges and scientists will continue working to develop treatments to deal with the consequences of smoking.

We need to educate the public more regarding the harms of cigarette smoking, Liu said. My research may offer future medicines for lung diseases caused by cigarette smoking.

Under the umbrella of the Oklahoma Center for Adult Stem Cell Research (OCASCR), created with funding from the Oklahoma Tobacco Settlement Endowment Trust, these scientists have amassed groundbreaking findings in one of the fastest growing areas of medical research. Photo provided.

Liu has been conducting research in the field of lung biology and diseases for more than two decades.

However, his interests in adult stem cell therapy began in 2010 when OCASCR was established through a grant with TSET, which provided funding to Oklahoma researchers for stem cell research.

I probably would have never gotten my feet into stem cell research without OCASCR funding support, he said. OCASCR funding also facilitated the establishment of the Interdisciplinary Program in Regenerative Medicine at OSU.

These days, Liu finds himself fully immersed in the exciting world of adult stem cell research and collaborating with some of Oklahomas best scientific minds.

Dr. Liu and his colleagues are really thriving. It was clear seven years ago that regenerative medicine was a hot topic and we already had excellent scientists in the Oklahoma, said Dr. Paul Kincade, founding scientific director of OCASCR. All they needed was some resources to re-direct and support their efforts. OSU investigators are using instruments and research grants supplied by OCASCR to compete with groups worldwide. TSET can point to their achievements with pride.

The Oklahoma Center for Adult Stem Cell Research represents collaboration between scientists all across the state, aiming to promote studies by Oklahoma scientists who are working with stem cells present in adult tissues.

The center opened in 2010 and has enhanced adult stem cell research by providing grant funding for researchers, encouraging recruitment of scientists and providing education to the people of Oklahoma.

We are fortunate that the collaboration at the Oklahoma Center for Adult Stem Cell Research is yielding such positive results, said John Woods, TSET executive director. This research is leading to ground breaking discoveries and attracting new researchers to the field. TSET is proud to fund that investments for Oklahomans.

Funding research is a major focus for TSET and it comes with benefits reaching beyond the lab. For every $1 TSET has invested at OCASCR, scientists have been able to attract an additional $4 for research at Oklahoma institutions, TSET officials said.

TSET also supports medical research conducted by the Stephenson Cancer Center and the Oklahoma Tobacco Research Center.

For more information, visit http://www.ocascr.org.

Go here to read the rest:
OCASCR scientists make progress in TSET-funded adult stem cell ... - NewsOK.com

Scientists at the University of Illinois say they have developed a new technique of genetic engineering for basic and applied biological research and medicine. Their work ("Programmable DNA-Guided Artificial Restriction Enzymes"), reported inACS Synthetic Biology,could open new doors in genomic research by improving the precision and adherence of sliced DNA, according to the investigators.

"Using our technology, we can create highly active artificial restriction enzymes with virtually any sequence specificity and defined sticky ends of varying length," said Huimin Zhao, Ph.,D., professor of chemical and biomolecular engineering, who leads a synthetic biology research group at the Carl R. Woese Institute for Genomic Biology at Illinois. "This is a rare example in biotechnology where a desired biological function or reagent can be readily and precisely designed in a rational manner."

Restriction enzymes cut DNA at a specific site and create a space wherein foreign DNA can be introduced for gene-editing purposes. This process is not achieved only by naturally occurring restriction enzymes; artificial restriction enzymes, or AREs, have risen to prominence in recent years. CRISPR/Cas9, a bacterial immune system used for "cut-and-paste" gene editing, and TALENs, or transcription activator-like effector nucleases, which are modified restriction enzymes, are two popular examples of such techniques.

Though useful in genetic engineering, no AREs generate defined "sticky ends"an uneven break in the DNA ladder structure that leaves complementary overhangs, improving adhesion when introducing new DNA. "If you can cleave two different DNA samples with the same restriction enzyme, the sticky ends that are generated are complementary," explained graduate student Behnam Enghiad. "They will hybridize with each other, and if you use a ligase, you can stick them together."

However, restriction enzymes themselves have a critical drawback: the recognition sequence that prompts them to cut is very short, usually only four to eight base pairs. Because the enzymes will cut anywhere that sequence appears, researchers rely on finding a restriction enzyme whose cut site appears only once in the genome of their organism or plasmid, an often difficult proposition when the DNA at hand might be thousands of base pairs long.

This problem has been partially solved simply by the sheer number of restriction enzymes discovered: more than 3600 have been characterized, and over 250 are commercially available. "Just in our freezer, for our other research, we have probably over 100 different restriction enzymes," said Enghiad. "We look through them all whenever we want to assemble something. The chance of finding the unique restriction site is so low."

"Our new technology unifies all of those restriction enzymes into a single system consisting of one protein and two DNA guides. Not only have you replaced them, but you can now target sites that no available restriction enzymes can."

The new method creates AREs through the use of an Argonaute protein (PfAgo) taken fromPyrococcus furiosus, an archeal species. Led by a DNA guide, PfAgo is able to recognize much longer sequences when finding its cut site, increasing specificity and removing much of the obstacles posed by restriction enzymes. Furthermore, PfAgo can create longer sticky ends than even restriction enzymes, a substantial benefit as compared to other AREs.

"When we started, I was inspired by a paper about a related proteinTtAgo. It could use a DNA guide to cleave DNA, but only up to 70 degrees," continued Enghiad. "DNA strands start to separate over 75 degrees, which could allow a protein to create sticky ends. If there were a protein that was active at higher temperatures, I reasoned, that protein could be used as an artificial restriction enzyme. SoI started looking for that, and what I found was PfAgo."

In addition to replacing restriction enzymes in genetic engineering processes, Enghiad and Dr. Zhao believe their technology will have broad applications in the biological research. By creating arbitrary sticky ends, PfAgo could make assembly of large DNA molecules easier and would enable cloning of large DNA molecules, such as biochemical pathways and large genes.

The application of these techniques is broad-reaching, they say, ranging from discovery of new small-molecule drugs to engineering of microbial cell factories for synthesis of fuels and chemicals to molecular diagnostics of genetic diseases and pathogens, which are the areas Dr. Zhao and Enghiad are currently exploring.

"Due to its unprecedented simplicity and programmability (a single protein plus DNA guides for targeting), as well as accessibility...we expect PfAgo-based AREs will become a powerful and indispensable tool in all restriction enzyme or nuclease-enabled biotechnological applications and fundamental biological research," predicts Dr. Zhao. "It is to molecular biology as the CRISPR technology is to cell biology."

Originally posted here:
Revolutionizing Biotechnology with Artificial Restriction Enzymes ... - Genetic Engineering & Biotechnology News (press release)

The last five years have witnessed amazing acceleration of innovation in biotechnology. CRISPR will lead to precision gene editing that could vastly improve food crop yields and provide cures to cancer. Lightning-fast gene sequencing will enable early detection of cancer from a simple blood test. High-speed bulk data transfer allows the entire genomes of millions of people to be compared online in the search for cures to both common and rare diseases. Neuromorphic chips will accelerate the dawn of artificial intelligence, and smart prostheses will allow para- and quadriplegic patients to move, the deaf to hear, and the blind to see.

Discovery of synergies in applications that blur the boundaries of traditional science, technology, engineering, and mathematics will continue to fuel this exponential growth of innovation. In spite of this exuberant trend, it is important to remember that innovation and discovery often outpace the regulatory structures that ensure their best and most ethical use in society.

The bioethics field traditionally is interpreted as pertaining mainly to the medical interests of humans. It has dealt with five key issues: beneficence, non-maleficence, patient autonomy, social justice, and patient confidentiality. However, with the advent of nanotechnology and other technologies that allow inter-kingdom transfer of genetic material, a need exists to establish a broader interpretation. Theologian Brian Edgar1 notes that a more robust definition should comprise six key considerations: respect for the intrinsic value of all life, valuing human uniqueness, preserving organismal integrity, recognizing ecologic holism, minimizing future liability, and producing social benefit. These considerations, while not expected to provide all of the answers to ethical dilemmas faced by technological advancement, create a framework for productive discussion of the most important aspects of biotechnology.

As Christians, we must also acknowledge that we are made in the image of God2, and have the unique ability, of all created things, to have a relationship with our Creator. In thoughtfully considering the implications of having been thus created, we have the responsibility of honoring Him by not only valuing human life, but by valuing and caring for His creation as well. If we actively and consistently apply this principle to guide us in making decisions about the application of biotechnology, the benefits to ourselves and to our world will be tremendous.

Posted: February 10, 2017

See the original post:
Why Bioethics Matters in Biotechnology - Azusa Pacific University

Gum/tooth disease is a common complaint that comes with aging, which is the reason many elderly people lose their natural teeth with age. One thing many physicians and their patients are yet to realize is that tooth/gum trouble is a symptom of a much more serious health challenge. Pain in the joints is a well known symptom of Rheumatoid Arthritis, but a much less known fact is the relationship between arthritis and gum/tooth troubles. Physician/researcher Al Sears points this out when he says, But one problem with modern medicine is that specialists often miss the bigger picture. Every part of your body is biologically connected. And whats going on in your mouth can reveal a lot about your health.

New research studies published in the Nature Reviews Rheumatology journal provide evidence to corroborate Sears theory. Sears states, In a study published just a few weeks ago in the journal Nature Reviews Rheumatology, researchers followed 6,616 people for more than 10 years. They found that those who had moderate to severe gum disease had more than twice the risk of developing rheumatoid arthritis.

Sears continues, Other research suggests that clearing up gum disease could help prevent or treat Rheumatoid Arthritis. Case Western Reserve University School of Dental Medicine found that people who were treated for gum disease had significantly more improvement in their Rheumatoid Arthritis symptoms than those who were only treated for their Rheumatoid Arthritis.

There are a lot of bacteria in your mouth, something like 100 billion bacteria. The bacteria form a sticky film called plaque that hardens into tartar. Plaque and tartar cause inflammation in your gums. If you have plaque and tartar buildup, your gums may bleed when you brush your teeth. But those bacteria can also travel around your body. And left unchecked, they can cause inflammation in other parts of your body, like in your joints.

The good news is that treating gum troubles could treat or prevent Rheumatoid Arthritis. The Case Western Reserve University School of Dental Medicine study found that people who were treated for gum disease had significantly more improvement in their RA symptoms than those who were only treated for their Rheumatoid Arthritis. Sears continues, Scientists found that one of the bacteria involved in Periodontitis may trigger a process called citrullination. Researchers who study this process believe its what sparks the immune system and drives the cascade of events that lead to Rheumatoid Arthritis.

The secret of Healthy Teeth is therefore Healthy Joints. To prevent and treat your RA, simply take care of your teeth. Besides just brushing and flossing, do the following for healthy teeth AND joints:

To do this, in the morning before eating or drinking anything, gently swish one tablespoon of coconut oil in your mouth and between your teeth for 10 to 20 minutes. Dont swallow. Spit the used oil into the trash or a jar, not the sink. It will clog your plumbing. Rinse your mouth and brush your teeth as normal.

Read the original post:
Beat Arthritis by checking your teeth - The Nation Newspaper

Science Daily

Anti-cell death agent a potential treatment for vision loss associated with MS Science Daily A new therapeutic agent tested in a mouse model of multiple sclerosis (MS) produced anti-inflammatory activity and prevented loss of cells in the optic nerve, according to a new study by researchers in the Perelman School of Medicine at the University ... and more »

See more here:
Anti-cell death agent a potential treatment for vision loss associated with MS - Science Daily

Losing sight can make a patient feel broken and no longer whole, Rosemary Robinson explains

10 Feb 2017 by Selina Powell

Optometrists were cautioned against letting their own attitudes towards blindness get in the way of patient care during a 100% Optical presentation on vision loss and psychology.

Consultant ophthalmologist, Rosemary Robinson, emphasised that optometrists and ophthalmologists often viewed blindness as the ultimate professional failure.

Optical professionals react to loss of vision as other health professionals do to loss of life, Ms Robinson highlighted at the show (4-6 February, London ExCeL).

This sense of guilt was strongest in relation to vision loss from potentially curable conditions, she added.

However, optical professionals should not lose sight of the individual while treating a disease, Ms Robinson emphasised.

You are not responsible for vision loss but you are responsible for a patients overall care and treatmentEven if you cant make someone see better you can help make their quality of life better.

During her presentation, The Psychosocial Impact of Vision Loss, Ms Robinson detailed the different ways that blindness could affect a patient.

Some people who experienced vision loss felt broken and no longer whole, she explained.

Many people have a negative stereotype of a blind person and they self-impose that idea. They see themselves as an outsider and different from the rest of the community, she highlighted.

This effect on a persons self-esteem resulted in a patient reassessing their identity.

When blindness occurs its like theyve lost the previous person they were and they have to come to terms with who the new person with the sight loss is going to become, Ms Robinson explained.

Patients were often wary about how their vision would change in the future following a diagnosis.

When losing vision there is often the fear that they will go in to total darkness when, in fact, rarely this is the case, Ms Robinson added.

Losing the ability to see familiar faces and sights that bring people pleasure was a significant loss, she told delegates at the show.

Although a scene or object could be described to someone with sight loss, it was not the same, Ms Robinson explained.

It can be very different seeing it in your minds eye and it can be a source of frustration, she highlighted.

Ms Robinson detailed the different phases of coming to terms with sight loss, including trauma, shock and denial, mourning and withdrawal, and succumbing and depression.

The final stage was reassessment and reaffirmation, she added.

In this stage a patient began to view themselves as essentially the same as before their sight loss.

They just have to deal with life a little differently, Ms Robinson concluded.

Read more from the original source:
The psychological impact of blindness - AOP

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide

Continued here:
Biotechnology Considerations for the Unitary Patent System in Light of Brexit and Other Current Developments - JD Supra (press release)

Thursday, February 9, 2017 5:11 PM UTC

CAMBRIDGE, Mass., Feb. 09, 2017 -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the formation of a strategic partnership withAMS Biotechnology (AMSBIO). As part of the agreement, AMSBIO will distribute, market and sell Cellaria cell models and culture media throughoutEurope.The partnership enables Cellaria to better meet growing demand for its products outside the US.

Cellaria's unique patient-specific cell models and cell culture media products expand the current offering AMSBIO has for physiologically relevant cell culture products for drug discovery and other life science applications. Late in 2016, Cellaria announced the availability of new models for High Grade Serous and Endometriod Ovarian Cancer and an ER-positive breast model.

AMSBIOis a premier provider of quality life science research reagents and services helping customers develop innovative methods, processes, products and medicines. As a leading provider of scaffolds, matrices, kits and proteins for growing and screening spheroids and organoids, AMSBIO has contributed totheaccelerationof discovery programs in medical research.

Alex Sim, managing director at AMSBIO said, "The new partnership with Cellaria expands our existing portfolio by introducing patient-derived cancer models;allowing customers to conduct research and drug discoveryinitiatives to advanceprecision medicine.

"The unique value of our patient-specific cell models makesAMSBIOan ideal partner for Cellaria," said David Deems, chief executive officer at Cellaria. "Our products will expand theAMSBIOcancer product portfolio, and their technical expertise will enable them to support Cellaria's customers throughout Europe."

About Cellaria

Cellaria creates breakthrough oncology models that reflect the unique nature and complexity of a tumor. Using these informative models, cancer researchers are better able to select promising compounds and work towards personalized approaches that would enable physicians to identify the most effective treatment for each patient's needs. Cellaria's innovative products help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cancer cure. For more information, visitwww.cellariabio.comor to learn more about our cell models.

Human Life Could Be Extended Indefinitely, Study Suggests

Goosebumps, tears and tenderness: what it means to be moved

Are over-the-counter painkillers a waste of money?

Does an anomaly in the Earth's magnetic field portend a coming pole reversal?

Immunotherapy: Training the body to fight cancer

Do vegetarians live longer? Probably, but not because they're vegetarian

Could a contraceptive app be as good as the pill?

Some scientific explanations for alien abduction that aren't so out of this world

Society actually does want policies that benefit future generations

Six cosmic catastrophes that could wipe out life on Earth

Big Pharma Starts Using Cannabis For Making Drugs In Earnest

Do you need to worry if your baby has a flat head?

Here is the original post:
Cellaria Forms Strategic Partnership with AMS Biotechnology ... - EconoTimes

Bacteria links Crohn's disease to arthritis -- ScienceDaily Science Daily Patients with Crohn's disease, a type of inflammatory bowel disease (IBD) that causes abdominal pain and diarrhea, can also experience joint pain. In Crohn's ... and more »

Continue reading here:
Bacteria links Crohn's disease to arthritis -- ScienceDaily - Science Daily

A twisted ankle, broken hip or torn knee cartilage are all common injuries that can have medical ramifications long after the initial incident that causes them. Associated pain, inflammation, joint degeneration and even osteoarthritis can sideline a variety of different people: athletes, weekend warriors and patients who are either aging or inactive.

A team from Washington University in St. Louis was awarded $1.7 million from the National Institutes of Health (NIH) to develop a new therapeutic treatment that can deliver disease-modifying compounds in a manner to delay the development of inflammation, joint degeneration and arthritis with all the associated discomfort, disability and pain.

Were starting to see that many areas cant be reached via oral drug delivery, said Lori Setton, the Lucy & Stanley Lopata Distinguished Professor of Biomedical Engineering at the School of Engineering & Applied Science. For example, synovial joint fluid in the knee is almost optimized to rapidly clear compounds out of the joint. So were trying to trick the joint into being a good host for the therapeutic drugs we are delivering.

Setton, whose lab focuses on the role of mechanical factors in the breakdown and repair of soft tissues, says an intracellular compound called nuclear factor kappa B (NF-kB) is a main culprit in cellular breakdown, inflammation and pain after an injury. Shes working in the lab on a new solution using silk to deliver two specific molecules that can inhibit NF-kB at the site of a fracture or injury in an effort to stave off long-term joint damage.

Silk naturally doesnt interact with water, and, when you mix it with these molecules that also dont interact with water, they bind to each other very strongly, Setton said. We believe these selective compounds are therapeutically effective, but weve never been able to get them to their target site. By delivering them with the silk, we hope to get large doses to the target site with low toxicity and to have them remain in that compartment for longer periods of time.

In preliminary work with Tufts University investigator David Kaplan, Setton showed that model compounds can reside in the joint space about 5 times times longer if delivered with silk microparticles than if delivered alone. Silk is an attractive delivery vehicle because of its long history of safe clinical use, and Kaplan has received NIH support to promote translational uses of silk for medical and other applications. It was initial work in delivering silk to the knee joint that drove Setton to identify a suitable, disease-modifying compound for treatment of arthritis through collaborations with the Musculoskeletal Research Center at the Washington University School of Medicine.

Setton and her co-investigators at the School of Medicine including Youssef Abu-Amer, professor of orthopaedic surgery; Farshid Guilak, professor of orthopaedic surgery; and Gabriel Mbalaviele, associate professor of medicine in the Division of Bone and Mineral Diseases will soon start testing the new delivery system in animal models.

Delivering drugs orally to combat NF-kB-mediated problems at specific locations in the body, such as the injured knee, can be associated with harmful biological functions, Abu-Amer said. So this type of site-targeted approach to inhibit elevated NF-kB is essential if we want to provide effective treatment to the targeted site.

According to Setton, the enhanced drug-delivery system has the potential to prevent the onset and progression of joint damage in patients suffering from acute injuries, like minor joint fractures, ligament or meniscal tears.

Patients with joint trauma tend to go on to develop osteoarthritis at a higher rate compared to someone who doesnt have the injury, Setton said. Its a whole different type of arthritis development that we dont know a whole lot about, but we believe we can intervene early with new drug delivery and treatments, and prevent onset at a later stage.

Go here to see the original:
NIH awards $1.7 million to develop new arthritis treatment via silk ... - ScienceBlog.com (blog)

Etanercept vs. Monoclonal Antibody Tx Assessed in Rheumatoid Arthritis Monthly Prescribing Reference (registration) HealthDay News For patients with rheumatoid arthritis, etanercept is associated with lower risk for general infections and tuberculosis compared with monoclonal antibody treatment, according to a meta-analysis published online February 3 in the ...

See the original post:
Etanercept vs. Monoclonal Antibody Tx Assessed in Rheumatoid Arthritis - Monthly Prescribing Reference (registration)

Dr. Kenneth Simpson/College of Veterinary Medicine

E. coli bacteria (red), which are abundant in the immunoglobulin-A-coated microbiota of patients with a Crohn's disease-associated condition called spondyloarthritis, promote systemic inflammation. The blue circular structures depict the nuclei of cells called epithelial cells.

Patients with Crohns disease, a type of inflammatory bowel disease (IBD) that causes abdominal pain and diarrhea, can also experience joint pain. In Crohns disease, which affects about 800,000 Americans, the immune system can attack not only the bowels, but the musculoskeletal system as well, leading to spondyloarthritis, a painful condition that affects the spine and joints.

Research published Feb. 8 in Science Translational Medicine helps explain the connection between these seemingly unrelated symptoms, and could help physicians identify Crohns disease patients who are more likely to develop spondyloarthritis, enabling them to prescribe more effective therapies for both conditions.

New technology helped the researchers identify a type of E. coli bacteria found in people with Crohns disease that can trigger inflammation associated with spondyloarthritis, according to the study led by principal investigator Dr. Randy Longman and scientists from the Jill Roberts Center for Inflammatory Bowel Disease at NewYork-Presbyterian and Weill Cornell Medicine and the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine, microbiologists at Cornells College of Veterinary Medicine, and rheumatologists at the Hospital for Special Surgery (HSS).

The researchers used fecal samples from patients with IBD to identify bacteria in the gut that were coated with antibodies called immunoglobulin-A (IgA) that fight infection. Using flow cytometry, in which fluorescent probes are used to detect IgA-coated bacterial species, the researchers discovered that IgA-coated E. coli were abundant in fecal samples from patients with both Crohns disease and spondyloarthritis. Using patient samples and mouse models, they then linked these bacteria to cells that help regulate inflammation, known as Th17 cells, in people with autoimmune disorders.

Our findings may allow us to develop diagnostic tools to stratify Crohns patients with spondyloarthritis symptoms as well as patients at risk, said senior author Longman, assistant professor of medicine and director of the Jill Roberts Institute Longman Lab at Weill Cornell Medicine.

The investigators found that patients with Crohns disease and spondyloarthritis had higher levels of Th17 cells and that a protein called IL-23 triggers their activity. With the recent FDA approval of an anti-IL-23 medication for Crohns disease called ustekinumab, the findings may help physicians select therapies that target symptoms of both the bowels and the joints in these patients, Longman said.

Just sequencing the gut flora gives you an inventory of the bacteria, but does not tell you how they are perceived by the host immune system, said co-author Dr. Kenneth Simpson, professor of small animal medicine at the College of Veterinary Medicine, whose laboratory characterized theE. coli identified in the study. This approach is giving you a functional readout versus just an inventory.

Longman led the translational study along with co-author Dr. Ellen Scherl, director of the Roberts Center at NewYork-Presbyterian and Weill Cornell Medicine and the Jill Roberts Professor of Medicine at Weill Cornell Medicine, in collaboration with HSS rheumatologists and co-authors Dr. Lisa Mandl and Dr. Sergio Schwartzman. Initial funding for the work was provided by a pilot seed grant to foster collaborations between researchers in Ithaca and New York City, and has since been funded by the New York Crohns Foundation, the Charina Endowment Fund, the Center for Advanced Digestive Care, the Jill Roberts Institute for Research in IBD and the National Institutes of Health.

We knew there was smoke, but we didn't know where the fire was, said Simpson, who added that each collaborator provided unique expertise to uncover the findings. If we can block the ability of bacteria to induce inflammation, we may be able to kick Crohns disease and spondyloarthritis into remission.

Longman added: In IBD therapy, this is a step toward precision medicine to be able to clinically and biologically characterize a subtype of disease and then select the medicine that would best fit the patient with this type of inflammation. The results of this innovative study will start to inform our decision of which of our available medications will give the best chance of helping the individual patient.

Jen Singer is an editorial consultant for Weill Cornell Medicine.

Here is the original post:
Bacteria links Crohn's disease, arthritis, researchers find - Cornell Chronicle

Cost-effective stem cell treatment has to be the next revolution to transform personalised treatment of patients, said Hunterian Professorship Awardee A.A.Shetty. Speaking at a felicitation function, Dr. Shetty said there is a need to create awareness about stem cells and patient-specific treatment specifically designed for individuals.

It is going to be simple, with minimal complications. Our role is to make it cost effective. Once it happens, it will revolutionise treatment, said Dr. Shetty.

Surgery using stem cell technology is developing at a rapid pace and the role of stem cell therapy in Orthopaedics is gaining importance, said Trauma and Orthopaedic Speciality Hospital (TOSH) Managing Director S.H. Jaheer Hussain. The ability of stem cells to transform into bone and cartilage has given a new dimension in the treatment of osteoarthritis, fracture non union, ligament tears. Stem cells have shown significant clinical results in osteoarthritis and cartilage defects. Recent advances in stem cells centrifuging techniques have lead to the introduction of the new concept of single- stage knee cartilage regeneration.

Continue reading here:
'Economical stem cell treatment will revolutionise medicine' - The Hindu

Biotechnology and technology stocks are dominating our charts to watch this week, because they are displaying strong technical momentum.

Esperion Therapeutics Inc. ESPR, -2.81% is absolutely rocketing. The clinical-stage biopharma, which is focused on developing drugs that treat cardiovascular disease, popped 29% on Friday in response to good clinical news from Amgen AMGN, -0.54% regarding its own cardiovascular drug. The stock followed through on Monday and then again Tuesday, up $2.48, or 14%, to $20.14 on nearly 3.4 million shares traded. The stock pulled back toward the close, testing the bottom of its rising channel and resting in a tight wedge formation. This formation looks poised to break to the upside, with the next target at the channel top near $22.

Exelixis Inc. EXEL, +2.96% also had a strong session on Tuesday, up 54 cents, or 2.7%, to $20.57, on nearly 6.7 million shares traded. The cancer-drug companys stock needs to get through the rising trendline, near $21, connecting the most recent tops from September, December and January. The challenge beyond that would be the mid-channel line at around $22.75, a break through that could accelerate the stock into the high $20s.

Finisar Corp. FNSR, +2.44% edged above resistance on Tuesday, though closed slightly below it, up 76 cents, or 2.5%, to $30.89, on 2.7 million shares. The provider of optical subsystems for data communications recently traversed from the top of its price channel at around $37 in December to the bottom just above $27 on January 23, before rallying in the last two weeks. The stock did close above its 50-day moving average at $30.77 on Tuesday, and a break above current levels could get it to $33.25 next, followed by $35.50.

KEMET Corp. KEM, +1.88% has been in a steady rising channel since its breakout in November. The stock last week bounced off the channel bottom and rallied after the electronic-capacitor maker beat Wall Streets third-quarter earnings and revenue forecasts. The stock popped on Thursday and Friday, had an inside day on Monday (remaining inside the price range from Friday), and on Tuesday it had another solid day, up 17 cents, or 2.2%, to 7.81, on 652,900 shares traded. The stock looks like its about to take out the $7.90 area, and run up toward the channel top in the $9-$9.75 area.

See Harrys video chart analysis on these and other stocks.

The writer has no investments in the stocks mentioned in this column.

Harry Boxer is the founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis and live chart presentations.

Visit link:
Opinion: Harry Boxer's stocks to watch: biotechnology and technology - MarketWatch

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at the 19th Annual BIO CEO & Investor Conference 2017 on Monday, February 13, 2017, at 1:30 p.m. ET. The event will be held at the Waldorf-Astoria Hotel in New York, New York.

Interested parties can access a live audio webcast and slide presentation at http://www.aradigm.com. An archived presentation will be available on the Company's Web site for 30 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm is completing Phase 3 development of Pulmaquin (an investigational proprietary formulation of ciprofloxacin for inhalation) for the treatment of non-cystic fibrosis bronchiectasis. Aradigms inhaled ciprofloxacin formulations including Pulmaquin are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax. In addition, Aradigm has a pipeline composed of programs to prevent diseases in tobacco smokers through smoking cessation and a diagnostic program to detect aspirations of gastrointestinal fluid into the respiratory tract.

More information about Aradigm can be found at http://www.aradigm.com.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

Follow this link:
Aradigm to Present at the Biotechnology Industry Organization (BIO ... - Business Wire (press release)